+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Warts - Pipeline Review, H2 2020

  • ID: 5137245
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 112 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Cytovation AS
  • Feramda Ltd
  • Genetic Immunity Inc
  • Maruho Co Ltd
  • Orgenesis Inc
  • MORE
Warts - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2020, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 13, 5, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Cytovation AS
  • Feramda Ltd
  • Genetic Immunity Inc
  • Maruho Co Ltd
  • Orgenesis Inc
  • MORE
  • Introduction
  • Warts - Overview
  • Warts - Therapeutics Development
  • Warts - Therapeutics Assessment
  • Warts - Companies Involved in Therapeutics Development
  • Warts - Drug Profiles
  • Warts - Dormant Projects
  • Warts - Discontinued Products
  • Warts - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Warts, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Warts - Pipeline by Aclaris Therapeutics Inc, H2 2020
  • Warts - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, H2 2020
  • Warts - Pipeline by Chengdu Institute of Biological Products Co Ltd, H2 2020
  • Warts - Pipeline by Cutanea Life Sciences Inc, H2 2020
  • Warts - Pipeline by Cytovation AS, H2 2020
  • Warts - Pipeline by Etna Biotech Srl, H2 2020
  • Warts - Pipeline by Feramda Ltd, H2 2020
  • Warts - Pipeline by G&E Corp, H2 2020
  • Warts - Pipeline by Genetic Immunity Inc, H2 2020
  • Warts - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, H2 2020
  • Warts - Pipeline by Henderson Morley Plc (Inactive), H2 2020
  • Warts - Pipeline by KinoPharma Inc, H2 2020
  • Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2020
  • Warts - Pipeline by Maruho Co Ltd, H2 2020
  • Warts - Pipeline by Nielsen Biosciences Inc, H2 2020
  • Warts - Pipeline by Orgenesis Inc, H2 2020
  • Warts - Pipeline by Peritech Pharma, H2 2020
  • Warts - Pipeline by Phio Pharmaceuticals Corp, H2 2020
  • Warts - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2020
  • Warts - Pipeline by Shanghai Zerun Biotechnology Co Ltd, H2 2020
  • Warts - Pipeline by Veloce BioPharma LLC, H2 2020
  • Warts - Pipeline by Verrica Pharmaceuticals Inc, H2 2020
  • Warts - Pipeline by Xiamen Innovax Biotech Co Ltd, H2 2020
  • Warts - Dormant Projects, H2 2020
  • Warts - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Warts - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Warts, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Aclaris Therapeutics Inc
  • Beijing Kangle Guardian Biotechnology Co Ltd
  • Chengdu Institute of Biological Products Co Ltd
  • Cutanea Life Sciences Inc
  • Cytovation AS
  • Etna Biotech Srl
  • Feramda Ltd
  • G&E Corp
  • Genetic Immunity Inc
  • Hefei Ruichengsheng Biotechnology Co Ltd
  • Henderson Morley Plc (Inactive)
  • KinoPharma Inc
  • Laboratories Ojer Pharma SL
  • Maruho Co Ltd
  • Nielsen Biosciences Inc
  • Orgenesis Inc
  • Peritech Pharma
  • Phio Pharmaceuticals Corp
  • Shanghai Bovax Biotechnology Co Ltd
  • Shanghai Zerun Biotechnology Co Ltd
  • Veloce BioPharma LLC
  • Verrica Pharmaceuticals Inc
  • Xiamen Innovax Biotech Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll